Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Study With a Loading Dose of Clofazimine in Adult Patients With Nontuberculous Mycobacterial Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The participant is diagnosed with pulmonary or extrapulmonary NTM disease and is eligible for treatment with CFZ~* The participant is at least 18 years of age~* The participant has a body weight (in light clothing and with no shoes) of at least 45 kg~* The participant is able and willing to provide written, informed consent~Exclusion Criteria:~* The participant is in poor general condition where participation in the study cannot be accepted per discretion of the Investigator~* There is evidence showing the participant has clinically significant metabolic, gastrointestinal, or other abnormalities that could possibly alter the PK of CFZ~* The participant is diagnosed with cystic fibrosis~* The participant has a prolongation of the QTc interval, \> 450 milliseconds for males and \> 460 milliseconds for females, on the screening ECG~* The participant has abnormal alanine aminotransferase (ALT) and/or aspartate transferase (AST) levels of \> 3 times the upper limit of the laboratory reference range at screening~* The participant is pregnant or is using inadequate contraceptive measures (if applicable)~* The participant is breastfeeding (if applicable)~* The participant has a known or suspected, current drug or alcohol abuse, that is, in the opinion of the Investigator, sufficient to compromise the safety or cooperation of the patient~* The participant has as history of allergy/hypersensitivity to CFZ~* The participant has received clofazimine in the past 3 months before inclusion with the exception of short-term use of no more than 7 days in the period of 1 to 3 months before inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Loading dose Clofazimine (Type: EXPERIMENTAL): All participants will receive an (experimental) oral loading dose regimen of 300 mg clofazimine (CFZ) once daily (= 3 capsules of 100 mg) for 4 weeks. Afterwards, all participants will continue with a standard oral dose of 100 mg clofazimine once daily (= 1 capsule of 100 mg) until a total 4 months of treatment with CFZ.

Based on this trial design, predict the completion outcome and termination type (if applicable).